Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738556 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14738012 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL3129629 | 1.00 | KDM4E (0.43) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14738301 | 0.85 | — | — | |
| SCHEMBL4730170 | 0.85 | — | — | |
| SCHEMBL16334572 | 0.85 | — | — | |
| SCHEMBL20579990 | 0.85 | — | — | |
| SCHEMBL14738443 | 0.85 | — | — | |
| SCHEMBL14738046 | 0.85 | KMT2A (0.50) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL15139869 | 0.85 | KMT2A (0.50) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809652-B1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | KDM4E 3019/4885MAPT 1994/4885KMT2A 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.